A small dose of apomorphine counteracts the deleterious effects of middle cerebral artery occlusion in different models
Abstract
Keywords
Full Text:
PDFReferences
Albrecht S. and Buerger E. Potential Neuroprotection Mechanisms in PD: Focus on Dopamine Agonist Pramipexole. Curr. Med. Res. Opin., 25: 2977-2987, 2009.
Backhauss C., Karkoutly C., Welsch M., Krieglstein J. A mause model of focal cerebral ischemia for screening neuroprotective drug effects. J. Pharmacol. Toxicol. Methods, 27: 27-32, 1992.
Battaglia G., Busceti C.L., Cuomo L., Giorgi F.S., Orzi F., De Blasi A., Nicoletti F., Ruggieri S., Fornai F. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice. Neuropharmacology, 42: 367-373, 2002a.
Battaglia G., Gesi M., Lenzi P., Busceti C.L., Soldani P., Orzi F., Rampello L., Nicoletti F., Ruggieri S, Fornai F. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity. Ann. N.Y. Acad. Sci., 965: 254-266, 2002b.
Caldeira M.V., Salazar I.L., Curcio M., Canzoniero L.M., Duarte C.B. Role of the ubiquitin-proteasome system in brain ischemia: friend or foe? Prog. Neurobiol., 112: 50-69, 2014.
Castri P., Busceti C., Battaglia G., Girardi F., Cavallari M., Orzi F., Fornai F. Protection by Apomorphine in Two Independent Models of Acute Inhibition of Oxidative Metabolism in Rodents. Clin. Exp. Hypertens., 28: 387-394, 2006.
Fornai F., Battaglia G., Gesi M., Orzi F., Nicoletti F., Ruggieri S. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res., 898: 27-35, 2001.
Graham S.H. and Liu H. Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia. Ageing Res. Rev., 34: 30-38, 2017.
Hara H. Molecular mechanism of neuroprotective drugs against oxidative stress-induced neuronal cell death. Yakugaku Zasshi, 127: 1199-1205, 2007.
Hart R.G., Pearce L.A., Ravina B.M., Yaltho T.C., Marler J.R. Neuroprotection Trials in Parkinson’s Disease: Systematic Review. Mov. Disord., 24: 647-654, 2009.
Himeno E., Ohyagi Y., Ma L., Nakamura N., Miyoshi K., Sakae N., Motomura K., Soejima N., Yamasaki R., Hashimoto T., Tabira T., LaFerla F.M., Kira J. Apomorphine Treatment in Alzheimer Mice Promoting Amyloid-β Degradation. Ann. Neurol., 69: 248-256, 2011.
Kyriazis M. Neuroprotective, anti-apoptotic effects of apomorphine. J. Anti. Aging. Med., 6: 21-28, 2003.
Madinier A., Wieloch T., Olsson R., Ruscher K. Impact of estrogen receptor beta activation on functional recovery after experimental stroke. Behav. Brain Res., 261: 282-288, 2014.
McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., Moots R.J. Dopamine Receptor Expression on Human T- and B-Lymphocytes, Monocytes, Neutrophils, Eosinophils and NK Cells: A Flow Cytometric Study. J. Neuroimmunol., 132: 34-40, 2002.
Miyazaki I., Asanuma M., Diaz-Corrales F.J., Miyoshi K., Ogawa N. Direct Evidence for Expression of Dopamine Receptors in Astrocytes from Basal Ganglia. Brain Res., 1029: 120-130, 2004.
Moyanova S., Kirov R., Kortenska L. Multi-unit activity suppression and sensorimotor deficits after endothelin-1-induced middle cerebral artery occlusion in conscious rats. J. Neurol. Sci., 212: 59-67, 2003.
Murer M.G., Dziewczapolski G., Menalled L.B., García M.C., Agid Y., Gershanik O., Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol., 43: 561-575, 1998.
Ohta K., Kuno S., Mizuta I., Fujinami A., Matsui H., Ohta M. Effects of Dopamine Agonists Bromocriptine, Pergolide, Cabergoline, and SKF-38393 on GDNF, NGF, and BDNF Synthesis in Cultured Mouse Astrocytes. Life Sci., 73: 617-626, 2003.
Osborne K.A., Shigeno T., Balarsky A.M., Ford I., McCulloch J., Teasdale G.M., Graham D.I. Quantitative assessment of early brain damage in a rat model of focal cerebral ischemia. J. Neurol. Neurosurg. Psychiat. 50: 402-410, 1987.
Paxinos G. and Watson C. The rat brain in stereotaxic coordinates. (Compact 3rd ed) 1998, New York: Academic Press.
Radad K., Gille G., Rausch W.D. Short Review on Dopamine Agonists: Insight into Clinical and Research Studies Relevant of Parkinson’s Disease. Pharmacol. Rep., 57: 701-712, 2005.
Ruscher K., Kuric E, Wieloch T. Levodopa Treatment Improves Functional Recovery after Experimental Stroke. Stroke, 43: 507-513, 2012.
Sarkar C., Basu B., Chakroborty D., Dasgupta P.S., Basu S. The Immunoregulatory Role of Dopamine: An Update. Brain. Behav. Immun., 24: 525-528, 2010.
Refbacks
- There are currently no refbacks.